Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 1
1993 1
1994 2
1995 1
1996 1
1999 3
2001 1
2002 1
2004 1
2005 1
2006 1
2007 1
2008 2
2010 2
2011 1
2012 1
2013 1
2015 1
2018 1
2022 7
2023 37
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for legorreta p
Search for Legoretta P instead (2 results)
Chromophobe renal cell carcinoma.
Henske EP, Cheng L, Hakimi AA, Choueiri TK, Braun DA. Henske EP, et al. Cancer Cell. 2023 Aug 14;41(8):1383-1388. doi: 10.1016/j.ccell.2023.07.006. Epub 2023 Aug 3. Cancer Cell. 2023. PMID: 37541245
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer.
Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I, Peng X, Al Janabi H, Huang G, Mittlesteadt J, Cheng M, Bhardwaj A, Ashfeld BL, Kao KR, Maeda DY, Dai X, Wiest O, Blagg BSJ, Lu X, Cheng L, Wan J, Lu X. Zhu Y, et al. Sci Immunol. 2023 Mar 17;8(81):eade4656. doi: 10.1126/sciimmunol.ade4656. Epub 2023 Mar 10. Sci Immunol. 2023. PMID: 36897957 Free PMC article.
Apoptotic cell death in disease-Current understanding of the NCCD 2023.
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Aqeilan RI, Arama E, Baehrecke EH, Balachandran S, Bano D, Barlev NA, Bartek J, Bazan NG, Becker C, Bernassola F, Bertrand MJM, Bianchi ME, Blagosklonny MV, Blander JM, Blandino G, Blomgren K, Borner C, Bortner CD, Bove P, Boya P, Brenner C, Broz P, Brunner T, Damgaard RB, Calin GA, Campanella M, Candi E, Carbone M, Carmona-Gutierrez D, Cecconi F, Chan FK, Chen GQ, Chen Q, Chen YH, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Ciliberto G, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Daugaard M, Dawson TM, Dawson VL, De Maria R, De Strooper B, Debatin KM, Deberardinis RJ, Degterev A, Del Sal G, Deshmukh M, Di Virgilio F, Diederich M, Dixon SJ, Dynlacht BD, El-Deiry WS, Elrod JW, Engeland K, Fimia GM, Galassi C, Ganini C, Garcia-Saez AJ, Garg AD, Garrido C, Gavathiotis E, Gerlic M, Ghosh S, Green DR, Greene LA, Gronemeyer H, Häcker G, Hajnóczky G, Hardwick JM, Haupt Y, He S, Heery DM, Hengartner MO, Hetz C, Hildeman DA, Ichijo H, Inoue S, Jäättelä M, Janic A, Joseph B, Jost PJ, Kanneganti TD, Karin M, Kashkar H, Kaufmann T, Kelly … See abstract for full author list ➔ Vitale I, et al. Cell Death Differ. 2023 May;30(5):1097-1154. doi: 10.1038/s41418-023-01153-w. Epub 2023 Apr 26. Cell Death Differ. 2023. PMID: 37100955 Free PMC article. Review.
Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y, Wang H, Golijanin B, Amin A, Lee J, Sikov M, Hyams E, Pareek G, Carneiro BA, Mega AE, Lagos GG, Wang L, Wang Z, Cheng L. Shi Y, et al. Urol Oncol. 2024 May;42(5):144-154. doi: 10.1016/j.urolonc.2024.01.037. Epub 2024 Mar 13. Urol Oncol. 2024. PMID: 38485644 Review.
For example, PTEN mutations, which cause uncontrolled cell growth, are frequently present in IDC-P and CC-P. Germline mutations in homologous DNA recombination repair (HRR) genes (e.g., BRCA1, BRCA2, ATM, PALB2, and CHEK2) are discovered in 40% of patients with IDC- …
For example, PTEN mutations, which cause uncontrolled cell growth, are frequently present in IDC-P and CC-P. Germline mutation …
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Yap TA, et al. Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5. Nat Med. 2023. PMID: 37277454 Free PMC article. Clinical Trial.
PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models.
Zdioruk M, Jimenez-Macias JL, Nowicki MO, Manz KE, Pennell KD, Koch MS, Finkelberg T, Wu B, Boucher P, Takeda Y, Li W, Piranlioglu R, Ling AL, Chiocca EA, Lawler SE. Zdioruk M, et al. Cell Rep Med. 2023 May 16;4(5):101019. doi: 10.1016/j.xcrm.2023.101019. Epub 2023 Apr 14. Cell Rep Med. 2023. PMID: 37060903 Free PMC article.
73 results